<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A double-blind, placebo-controlled randomized study of <z:chebi fb="1" ids="4315">danazol</z:chebi> was performed to determine if the drug has a therapeutic effect in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty evaluable patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were randomized to receive, a single daily oral dose of either <z:chebi fb="1" ids="4315">danazol</z:chebi> (600 mg/day) or matching placebo </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment was continued, when possible, for a period of 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>Response was based on clinical course, peripheral blood counts with white blood cells differential, platelet, reticulocyte at specified intervals </plain></SENT>
<SENT sid="4" pm="."><plain>Repeat bone marrow aspirates and biopsy were also done </plain></SENT>
<SENT sid="5" pm="."><plain>Significant differences was observed between the treatment groups in response to test drug </plain></SENT>
<SENT sid="6" pm="."><plain>Increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, granulocytes, platelets and improvement in survival was noted in <z:chebi fb="1" ids="4315">danazol</z:chebi> group </plain></SENT>
<SENT sid="7" pm="."><plain>Side effects were minimal </plain></SENT>
<SENT sid="8" pm="."><plain>Our study suggests that <z:chebi fb="1" ids="4315">danazol</z:chebi> exerts a beneficial therapeutic effect in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>